Clearside Biomedical, Inc. today announced four poster presentations associated with suprachoroidal drug administration will be presented at the 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), May 1-5, 2016, in Seattle, WA.

The following poster presentations are scheduled during the ARVO Annual Meeting:

  • Patel S, Kissner J, Zarnitsyn V, Farjo R, Noronha G. Efficacy of Suprachoroidal Aflibercept in a Laser Induced Choroidal Neovascularization Model. [286-B0319. May 1, 8:30 a.m.-10:15 a.m., Exhibit Hall]
  • Taraborelli D, Burke B, Noronha G. Ocular Tolerability and Toxicokinetics of Suprachoroidally Administered CLS-TA, Triamcinolone Acetonide Injectable Suspension, in Combination with Intravitreal Eylea® in Rabbits. [296-B0329. May 1, 8:30 a.m.-10:15 a.m., Exhibit Hall]
  • Kissner J, Patel S, Prusakiewicz J, Alton D, Bikzhanova G, Geisler L, Burke B, Noronha G. Pharmacokinetics Including Ocular Distribution Characteristics of Suprachoroidally Administered CLS011A in Rabbits Could be Beneficial for a Wet AMD Therapeutic Candidate. [4002-B0180. May 3, 3:45 p.m.-5:30 p.m., Exhibit Hall]
  • Zarnitsyn V, Patel S, Yoo J, Noronha G. Characterization of Suprachoroidal Injection in Multiple Species. [5032-B0238. May 4, 11:00 a.m.-12:45 p.m., Exhibit Hall]

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye using Clearside’s proprietary suprachoroidal space (SCS™) microinjector to reach diseased tissue through the suprachoroidal space. Clearside holds intellectual property protecting the delivery of drugs of any type through the suprachoroidal space to reach the back of the eye. Clearside has a portfolio of clinical and pre-clinical programs using drug administration through the suprachoroidal space to provide a route of access to treat diseases of the back-of-the-eye like retinal vein occlusion (RVO), uveitis, wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Clearside is currently enrolling patients in a Phase 3 clinical trial (Peachtree) for the treatment of patients with macular edema associated with non-infectious uveitis and has initiated IND-enabling studies for the treatment of wet AMD. Visit for more information.

Clearside Biomedical, Inc.
Charles Deignan, 678-270-4005
Chief Financial Officer
The Trout Group
Matthew Beck, 646-378-2933

VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative enterprise technology and transact. Discover our Briefings.